| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(05)62154-X |
| P698 | PubMed publication ID | 8988109 |
| P2093 | author name string | S W Schalm | |
| P2860 | cites work | 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. | Q40495828 |
| Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine | Q45768670 | ||
| Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients | Q45784197 | ||
| A preliminary trial of lamivudine for chronic hepatitis B infection | Q71523548 | ||
| P433 | issue | 9044 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lamivudine | Q422631 |
| P304 | page(s) | 3-4 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Clinical implications of lamivudine resistance by HBV | |
| P478 | volume | 349 |
| Q35594472 | Combination therapy for hepatitis B |
| Q44071061 | Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment |
| Q45286354 | Developing strategies for prevention and treatment of recurrent HBV in liver transplantation |
| Q45755644 | Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy |
| Q45367247 | Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy |
| Q35621634 | Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics |
| Q45740593 | In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy - a clinical note |
| Q28348802 | Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis |
| Q39400111 | Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study |
| Q37586265 | Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy |
| Q34922618 | Role of antiviral therapy in the prevention of hepatocellular carcinoma |
| Q40605234 | The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. |
| Q54141530 | Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. |
| Q34027579 | Treatment of chronic hepatitis B: new antiviral therapies. |
| Q40556453 | Virological and biochemical relapse according to YMDD motif mutant type during long‐term lamivudine monotherapy |
Search more.